 Biogen Inc. shares BIIB, -0.43 rose 4.7 in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimers disease failed to meet its main goal. German-listed shares of MorphoSys MOR, -29.66 MOR, 2.44 fell 30 on the news, while Roche ROG, -3.24 was down 4 in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment MCI due to Alzheimers and mild Alzheimers dementia did not meet their primary endpoint of slowing clinical decline. 